Condition: Advanced Solid Tumor · Head and Neck Squamous Cell Carcinoma · Sponsor: Coherus Oncology, Inc.
This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.
This description comes directly from the study's public registry record.
Clinical Operations Team · 800-794-5434 · clinicaltrials@coherus.com
Always discuss trial participation with your own doctor first.
| Hoag Memorial Hospital | Newport Beach, California, United States | Withdrawn |
| FOMAT Medical Research | Oxnard, California, United States | Withdrawn |
| Stanford Cancer Center | Palo Alto, California, United States | Recruiting |
| SCRI Lake Nona DDU (FL Cancer Specialists) | Orlando, Florida, United States | Withdrawn |
| Emory Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| Hope & Healing Cancer Services | Hinsdale, Illinois, United States | Withdrawn |
| University of Louisville | Louisville, Kentucky, United States | Recruiting |
| University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center | Detroit, Michigan, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| University of Cincinnati | Cincinnati, Ohio, United States | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05635643